Join this live webinar to learn more.
As demand intensifies for more predictive and translational cardiac safety models, the field is entering a pivotal moment. A promising new approach—non-human primate (cynomolgus, NHP-C) iPSC-derived ventricular cardiomyocytes—is poised to reshape how scientists bridge the gap between animal models and human cardiac safety pharmacology.
Join leading industry experts for this insightful webinar for an exciting look at next-generation approaches for delivering greater confidence in preclinical testing. See how combining large-scale bioreactor production with rigorous functional characterization, NHP-C iPSC-derived cardiomyocytes provide a highly consistent and physiologically relevant model that mirrors human-like cardiac responses.
We’ll explore:
- How NHP-C cardiomyocytes achieve >90% purity with stable, reproducible beating activity across wells
- Demonstrated responses to clinically relevant compounds such as dofetilide, nifedipine, and isoproterenol
- How high-throughput MEA-based analysis, coupled with contractility assessments, is advancing predictive toxicology
- The implications for improving the reliability and translational value of cardiac safety studies
- And more
Don’t miss this important deep dive into how cutting-edge cellular models can redefine the future of cardiac safety science. Register today!
Offered Free by: Ncardia
See All Resources from: Ncardia
